India, April 4 -- Monash University researchers are advancing a new therapeutic approach for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through biotechnology company xCystence Bio, supported by a syndicated pre-seed investment.

Launched in 2023 with grant funding from Brandon BioCatalyst's CUREator incubator, the company brings together Monash University expertise in kidney disease biology and medicinal chemistry to develop new therapies for the condition. It builds on research led by scientists across the Monash Biomedicine Discovery Institute (BDI) in the Faculty of Medicine, Nursing and Health Sciences (MNHS) and the Monash Institute of Pharmaceutical Sciences (MIPS) within the Faculty of Pharmacy and Pharmaceutical Sciences...